# Fortive Corp: financial statements, quarterly

FTV · NYSE · CIK 1659166 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ftv.md) · [Financials](/companies/ftv/financials.md) · [Filings](/companies/ftv/filings.md) · [Insiders](/companies/ftv/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ftv/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) | Q3 FY2026 (2026-10-02) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [(568) d](/filings/0001659166-26-000007.md) | [984](/filings/0001659166-26-000007.md) | [1,020](/filings/0001659166-26-000007.md) | [1,004](/filings/0001659166-26-000007.md) | [1,073](/filings/0001659166-26-000007.md) | [993](/filings/0001659166-26-000013.md) | [1,016](/filings/0001659166-26-000034.md) | [1,027](/filings/0001659166-26-000040.md) | [1,123](/filings/0001659166-26-000007.md) | [1,069](/filings/0001659166-26-000013.md) | [1,097](/filings/0001659166-26-000034.md) | [1,108](/filings/0001659166-26-000040.md) |
| Cost of revenue | $m | [(398) d](/filings/0001659166-26-000007.md) | [620](/filings/0001659166-25-000080.md) | [624](/filings/0001659166-25-000120.md) | [362](/filings/0001659166-25-000131.md) | [377 d](/filings/0001659166-26-000007.md) | [356](/filings/0001659166-26-000013.md) | [371](/filings/0001659166-26-000034.md) | [378](/filings/0001659166-26-000040.md) | [414 d](/filings/0001659166-26-000007.md) | [394](/filings/0001659166-26-000013.md) | [402](/filings/0001659166-26-000034.md) | [397](/filings/0001659166-26-000040.md) |
| Gross profit | $m | [(170) d](/filings/0001659166-26-000007.md) | [629](/filings/0001659166-26-000007.md) | [654](/filings/0001659166-26-000007.md) | [642](/filings/0001659166-26-000007.md) | [696](/filings/0001659166-26-000007.md) | [638](/filings/0001659166-26-000013.md) | [646](/filings/0001659166-26-000034.md) | [649](/filings/0001659166-26-000040.md) | [709](/filings/0001659166-26-000007.md) | [676](/filings/0001659166-26-000013.md) | [695](/filings/0001659166-26-000034.md) | [711](/filings/0001659166-26-000040.md) |
| Research and development | $m | [(61.6) d](/filings/0001659166-26-000007.md) | [104](/filings/0001659166-25-000080.md) | [101](/filings/0001659166-25-000120.md) | [62.0](/filings/0001659166-25-000131.md) | [65.2 d](/filings/0001659166-26-000007.md) | [64.0](/filings/0001659166-26-000013.md) | [67.2](/filings/0001659166-26-000034.md) | [62.0](/filings/0001659166-26-000040.md) | [66.0 d](/filings/0001659166-26-000007.md) | [66.5](/filings/0001659166-26-000013.md) | [67.5](/filings/0001659166-26-000034.md) | [68.2](/filings/0001659166-26-000040.md) |
| Selling, general and administrative | $m | [141 d](/filings/0001659166-26-000007.md) | [561](/filings/0001659166-25-000080.md) | [525](/filings/0001659166-25-000120.md) | [408](/filings/0001659166-25-000131.md) | [418 d](/filings/0001659166-26-000007.md) | [408](/filings/0001659166-26-000013.md) | [409](/filings/0001659166-26-000034.md) | [428](/filings/0001659166-26-000040.md) | [417 d](/filings/0001659166-26-000007.md) | [417](/filings/0001659166-26-000013.md) | [418](/filings/0001659166-26-000034.md) | [407](/filings/0001659166-26-000040.md) |
| Operating income | $m | [(249) d](/filings/0001659166-26-000007.md) | [150](/filings/0001659166-26-000007.md) | [182](/filings/0001659166-26-000007.md) | [172](/filings/0001659166-26-000007.md) | [212](/filings/0001659166-26-000007.md) | [165](/filings/0001659166-26-000013.md) | [170](/filings/0001659166-26-000034.md) | [160](/filings/0001659166-26-000040.md) | [226](/filings/0001659166-26-000007.md) | [192](/filings/0001659166-26-000013.md) | [210](/filings/0001659166-26-000034.md) | [236](/filings/0001659166-26-000040.md) |
| Interest expense | $m | [(219) d](/filings/0001659166-26-000007.md) | [(44.0)](/filings/0001659166-25-000080.md) | [(38.7)](/filings/0001659166-25-000120.md) | [(37.1)](/filings/0001659166-25-000131.md) | [(33.0) d](/filings/0001659166-26-000007.md) | [(32.0)](/filings/0001659166-26-000013.md) | [(32.1)](/filings/0001659166-26-000034.md) | [(25.4)](/filings/0001659166-26-000040.md) | [(31.0) d](/filings/0001659166-26-000007.md) | [(31.6)](/filings/0001659166-26-000013.md) | [(35.4)](/filings/0001659166-26-000034.md) | [(38.8)](/filings/0001659166-26-000040.md) |
| Income tax | $m | [(88.0) d](/filings/0001659166-26-000007.md) | [26.6](/filings/0001659166-25-000080.md) | [33.6](/filings/0001659166-25-000120.md) | [(2.4)](/filings/0001659166-25-000131.md) | [(13.0) d](/filings/0001659166-26-000007.md) | [21.1](/filings/0001659166-26-000013.md) | [28.0](/filings/0001659166-26-000034.md) | [18.0](/filings/0001659166-26-000040.md) | [2.4 d](/filings/0001659166-26-000007.md) | [27.2](/filings/0001659166-26-000013.md) | [22.2](/filings/0001659166-26-000034.md) | [29.8](/filings/0001659166-26-000040.md) |
| Net income | $m | [265 d](/filings/0001659166-26-000007.md) | [207](/filings/0001659166-25-000080.md) | [195](/filings/0001659166-25-000120.md) | [222](/filings/0001659166-25-000131.md) | [209](/filings/0001659166-26-000007.md) | [172](/filings/0001659166-26-000013.md) | [167](/filings/0001659166-26-000034.md) | [55.0](/filings/0001659166-26-000040.md) | [186](/filings/0001659166-26-000007.md) | [136](/filings/0001659166-26-000013.md) | [157](/filings/0001659166-26-000034.md) | [173](/filings/0001659166-26-000040.md) |
| Diluted EPS | $ per share | not reported | [0.58](/filings/0001659166-26-000007.md) | [0.55](/filings/0001659166-26-000007.md) | [0.63](/filings/0001659166-26-000007.md) | [0.60](/filings/0001659166-26-000007.md) | [0.50](/filings/0001659166-26-000013.md) | [0.49](/filings/0001659166-26-000034.md) | [0.16](/filings/0001659166-26-000040.md) | [0.58](/filings/0001659166-26-000007.md) | [0.44](/filings/0001659166-26-000013.md) | [0.51](/filings/0001659166-26-000034.md) | [0.57](/filings/0001659166-26-000040.md) |
| Basic EPS | $ per share | not reported | [0.59](/filings/0001659166-26-000007.md) | [0.56](/filings/0001659166-26-000007.md) | [0.63](/filings/0001659166-26-000007.md) | [0.61](/filings/0001659166-26-000007.md) | [0.50](/filings/0001659166-26-000013.md) | [0.49](/filings/0001659166-26-000034.md) | [0.17](/filings/0001659166-26-000040.md) | [0.59](/filings/0001659166-26-000007.md) | [0.44](/filings/0001659166-26-000013.md) | [0.52](/filings/0001659166-26-000034.md) | [0.57](/filings/0001659166-26-000040.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) | Q3 FY2026 (2026-10-02) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [1.9](/filings/0001659166-25-000024.md) | [0.7](/filings/0001659166-24-000108.md) | [0.6](/filings/0001659166-24-000148.md) | [0.8](/filings/0001659166-24-000162.md) | [0.8](/filings/0001659166-26-000007.md) | [0.9](/filings/0001659166-25-000080.md) | [1.8](/filings/0001659166-25-000120.md) | [0.4](/filings/0001659166-25-000131.md) | [0.4](/filings/0001659166-26-000040.md) | [0.4](/filings/0001659166-26-000013.md) | [0.4](/filings/0001659166-26-000034.md) | [0.4](/filings/0001659166-26-000040.md) |
| Current assets | $bn | [3.7](/filings/0001659166-25-000024.md) | [2.6](/filings/0001659166-24-000108.md) | [2.5](/filings/0001659166-24-000148.md) | [2.6](/filings/0001659166-24-000162.md) | [2.6](/filings/0001659166-26-000007.md) | [2.7](/filings/0001659166-25-000080.md) | [3.7](/filings/0001659166-25-000120.md) | [1.7](/filings/0001659166-25-000131.md) | [1.6](/filings/0001659166-26-000040.md) | [1.5](/filings/0001659166-26-000013.md) | [1.6](/filings/0001659166-26-000034.md) | [1.6](/filings/0001659166-26-000040.md) |
| Total assets | $bn | [16.9](/filings/0001659166-25-000024.md) | [17.5](/filings/0001659166-24-000108.md) | [17.3](/filings/0001659166-24-000148.md) | [17.5](/filings/0001659166-24-000162.md) | [17.0](/filings/0001659166-26-000007.md) | [17.1](/filings/0001659166-25-000080.md) | [18.2](/filings/0001659166-25-000120.md) | [11.9](/filings/0001659166-25-000131.md) | [11.7](/filings/0001659166-26-000040.md) | [11.6](/filings/0001659166-26-000013.md) | [11.6](/filings/0001659166-26-000034.md) | [11.5](/filings/0001659166-26-000040.md) |
| Current liabilities | $bn | [1.8](/filings/0001659166-25-000024.md) | [1.7](/filings/0001659166-24-000108.md) | [2.0](/filings/0001659166-24-000148.md) | [2.1](/filings/0001659166-24-000162.md) | [2.2](/filings/0001659166-26-000007.md) | [2.7](/filings/0001659166-25-000080.md) | [3.7](/filings/0001659166-25-000120.md) | [2.5](/filings/0001659166-25-000131.md) | [2.2](/filings/0001659166-26-000040.md) | [2.2](/filings/0001659166-26-000013.md) | [1.3](/filings/0001659166-26-000034.md) | [1.3](/filings/0001659166-26-000040.md) |
| Long-term debt | $bn | [3.6](/filings/0001659166-25-000024.md) | [3.9](/filings/0001659166-24-000108.md) | [3.4](/filings/0001659166-24-000148.md) | [3.5](/filings/0001659166-24-000162.md) | [3.3](/filings/0001659166-26-000007.md) | [2.9](/filings/0001659166-25-000080.md) | [2.9](/filings/0001659166-25-000120.md) | [2.1](/filings/0001659166-25-000131.md) | [2.3](/filings/0001659166-26-000040.md) | [2.6](/filings/0001659166-26-000013.md) | [3.5](/filings/0001659166-26-000034.md) | [3.5](/filings/0001659166-26-000040.md) |
| Current portion of debt | $bn | [0.0](/filings/0001659166-25-000024.md) | not reported | [0.4](/filings/0001659166-24-000148.md) | [0.4](/filings/0001659166-24-000162.md) | [0.4](/filings/0001659166-26-000007.md) | [0.9](/filings/0001659166-25-000080.md) | [1.9](/filings/0001659166-25-000120.md) | [1.2](/filings/0001659166-25-000131.md) | [0.9](/filings/0001659166-26-000040.md) | [0.9](/filings/0001659166-26-000013.md) | [0.0](/filings/0001659166-26-000034.md) | [0.0](/filings/0001659166-26-000040.md) |
| Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [10.3](/filings/0001659166-25-000024.md) | [10.5](/filings/0001659166-24-000108.md) | [10.5](/filings/0001659166-24-000148.md) | [10.6](/filings/0001659166-24-000162.md) | [10.2](/filings/0001659166-26-000007.md) | [10.2](/filings/0001659166-25-000080.md) | [10.4](/filings/0001659166-25-000120.md) | [6.5](/filings/0001659166-25-000131.md) | [6.5](/filings/0001659166-26-000040.md) | [6.1](/filings/0001659166-26-000013.md) | [6.1](/filings/0001659166-26-000034.md) | [5.9](/filings/0001659166-26-000040.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) | Q3 FY2026 (2026-10-02) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [447 d](/filings/0001659166-26-000007.md) | [257](/filings/0001659166-25-000080.md) | [309 d](/filings/0001659166-25-000120.md) | [459 d](/filings/0001659166-25-000131.md) | [502 d](/filings/0001659166-26-000007.md) | [242](/filings/0001659166-26-000013.md) | [311 d](/filings/0001659166-26-000034.md) | [164 d](/filings/0001659166-26-000040.md) | [366 d](/filings/0001659166-26-000007.md) | [235](/filings/0001659166-26-000013.md) | [286 d](/filings/0001659166-26-000034.md) | [313 d](/filings/0001659166-26-000040.md) |
| Capital expenditure | $m | [4.9 d](/filings/0001659166-26-000007.md) | [26.4](/filings/0001659166-25-000080.md) | [29.2](/filings/0001659166-25-000120.md) | [21.6](/filings/0001659166-25-000131.md) | [22.6 d](/filings/0001659166-26-000007.md) | [21.1](/filings/0001659166-26-000013.md) | [36.7](/filings/0001659166-25-000120.md) | [28.6](/filings/0001659166-25-000131.md) | [30.4 d](/filings/0001659166-26-000007.md) | [26.6](/filings/0001659166-26-000013.md) | [28.1 d](/filings/0001659166-26-000034.md) | [29.5 d](/filings/0001659166-26-000040.md) |
| Dividends paid | $m | [28.1 d](/filings/0001659166-26-000007.md) | [28.1](/filings/0001659166-25-000080.md) | [28.0 d](/filings/0001659166-25-000120.md) | [27.8 d](/filings/0001659166-25-000131.md) | [27.3 d](/filings/0001659166-26-000007.md) | [27.2](/filings/0001659166-26-000013.md) | [27.0 d](/filings/0001659166-26-000034.md) | [19.2 d](/filings/0001659166-26-000040.md) | [18.8 d](/filings/0001659166-26-000007.md) | [18.4](/filings/0001659166-26-000013.md) | [0.0 d](/filings/0001659166-26-000034.md) | [38.9 d](/filings/0001659166-26-000040.md) |
| Share repurchases | $m | [65.0 d](/filings/0001659166-26-000007.md) | [0.0](/filings/0001659166-25-000080.md) | [153 d](/filings/0001659166-25-000120.md) | [270 d](/filings/0001659166-25-000131.md) | [467 d](/filings/0001659166-26-000007.md) | [203](/filings/0001659166-26-000013.md) | [135 d](/filings/0001659166-26-000034.md) | [1,001 d](/filings/0001659166-26-000040.md) | [272 d](/filings/0001659166-26-000007.md) | [500](/filings/0001659166-26-000013.md) | [200 d](/filings/0001659166-26-000034.md) | [300 d](/filings/0001659166-26-000040.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) | Q3 FY2026 (2026-10-02) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [357](/filings/0001659166-24-000108.md) | [356](/filings/0001659166-24-000148.md) | [356](/filings/0001659166-24-000162.md) | [356](/filings/0001659166-25-000080.md) | [355](/filings/0001659166-25-000120.md) | [352](/filings/0001659166-25-000131.md) | [345](/filings/0001659166-26-000013.md) | [342](/filings/0001659166-26-000034.md) | [333](/filings/0001659166-26-000040.md) | [313](/filings/0001659166-26-000013.md) | [308](/filings/0001659166-26-000034.md) | [304](/filings/0001659166-26-000040.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 297,644,456 at 2026-10-23, from the cover of the [10-Q filed 2026-10-28](/filings/0001659166-26-000040.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 28, 2026, 08:27 ET. No prices; not investment advice.